Back to List View Graph View

Neurofilament Light Chain (NF-L)

NEFL (neurofilament light chain, also abbreviated as NfL) is a cytoplasmic protein and a major structural component of neuronal intermediate filaments.

Where the papers sit

20 papers from the last 6 months study Neurofilament Light Chain (NF-L) directly · updated from PubMed 30 Oct 2026

Study type 0 clinical trials · 15 observational · 5 human data

Themes 4 themes · 1 paradigm shift · 1 new direction

  • NfL and GFAP Brain Injury

    NfL and GFAP are being evaluated as blood or cerebrospinal-fluid indicators of brain injury across diverse neurological conditions. NfL more consistently reflects neuroaxonal damage and prognosis, while GFAP adds information about astroglial injury. Studies in myasthenia gravis, hepatic encephalopathy, epilepsy, autoimmune encephalitis, transient ischemic attack, and pediatric psychiatry are defining disease-specific utility. Assay choice, sample compartment, and clinical context remain important limitations.

    7 papers · 35%

  • Multiple Sclerosis Progression Monitoring

    Plasma NfL is moving toward routine monitoring of multiple sclerosis activity and progression beyond MRI. Higher levels and age-adjusted biological-age gaps are being linked to future clinical and radiological worsening, including EDSS outcomes. Real-world comparisons of Roche, Fujirebio, and Siemens assays are addressing analytical interchangeability. Age- and eGFR-adjusted reference ranges are also being developed, while GM2 gangliosidosis tests NfL as a surrogate outcome.

    6 papers · 30%

  • Alzheimer Disease Blood Biomarkers

    Blood biomarkers are being tested for earlier Alzheimer disease detection and longitudinal cognitive-risk assessment. Plasma proteomic measures, including GFAP and NfL, track cognitive decline across midlife, late life, and Down syndrome. Longitudinal sampling in Down syndrome is clarifying how biomarker trajectories relate to disease progression. Prion disease comparisons highlight the need to distinguish Alzheimer pathology from other rapidly progressive dementias.

    4 papers · 20%

  • Neuroaxonal Injury Monitoring

    Plasma NfL is emerging as a complementary marker of neuroaxonal injury across treatment-related, metabolic, and motor-neuron disease. Longitudinal measurements track vincristine-associated peripheral neuropathy alongside patient-reported outcomes. Diabetes studies connect NfL with diabetic peripheral neuropathy while accounting for age and renal function. In ALS, NfL outperforms inflammatory, metabolic, and CNS-barrier biomarkers for prognosis, supporting broader clinical use.

    3 papers · 15%

PARADIGM SHIFT

Plasma NfL results cannot be treated as interchangeable across automated assay platforms

The multiple-sclerosis cohorts comparing Roche Elecsys with Fujirebio Lumipulse and Siemens Atellica with Lumipulse found that, although measurements were correlated, raw values showed poor or only moderate agreement and proportional bias; alignment improved only after conversion to a common reference scale 42640285Aug 42378934Jun. This overturns the assumption that an NfL concentration has the same clinical meaning regardless of platform and makes assay-specific harmonization or conversion necessary before results can be compared or interpreted using shared thresholds.

NEW DIRECTION

NfL is used to construct a biological-age measure in multiple sclerosis

The neurofilament light chain-derived age-gap study in multiple sclerosis and controls assigned NfL a role beyond measuring current axonal injury or predicting disease activity: it used age-adjusted NfL values to estimate biological age and relate the difference from chronological age to disease characteristics 42802281Sep. This introduces NfL as an index of accelerated biological aging, rather than solely as a disease or treatment biomarker.

Papers

The 20 papers from the last 6 months that study Neurofilament Light Chain (NF-L) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

NfL and GFAP Brain Injury (7)
  1. PMID 42081930
  2. Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP. Journal of neurology · 9 Sept 2026 PMID 42711449
  3. Exploring serum biomarkers in paediatric psychiatry: the impact of NfL and GFAP. Translational psychiatry · 26 Aug 2026 PMID 42649149
  4. Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis. Neurology(R) neuroimmunology & neuroinflammation · 3 Aug 2026 PMID 42546229
  5. Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy. Liver international : official journal of the International Association for the Study of the Liver · 9 Jul 2026 PMID 42422896
  6. Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study. PloS one · 7 Jul 2026 PMID 42412876
  7. Differences in Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Tau Protein Levels in Patients with Temporal Lobe Epilepsy and Comorbid Depression. Molecular neurobiology · 26 May 2026 PMID 42189430
Multiple Sclerosis Progression Monitoring (6)
  1. Evaluating the neurofilament light chain-derived gap between biological and chronological age in multiple sclerosis and controls. Journal of neurology · 27 Sept 2026 PMID 42802281
  2. The predictive value of serum neurofilament light chain levels beyond MRI measures for clinical and radiological disease progression in the earliest stages of multiple sclerosis. Journal of neurology · 9 Sept 2026 PMID 42714661
  3. Real-world Roche Elecsys® and Fujirebio Lumipulse® inter-platform comparability and clinical validation of plasma neurofilament light chain in multiple sclerosis. Journal of neurology · 25 Aug 2026 PMID 42640285
  4. Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses. Journal of neurology · 17 Jul 2026 PMID 42467089
  5. Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosis. Multiple sclerosis and related disorders · 30 Jun 2026 PMID 42378934
  6. Age-Dependent z Scores and eGFR-Adjusted Reference Ranges for Neurofilament Light: A Practical Approach for Clinical Laboratories. Clinical chemistry · 28 May 2026 PMID 42207013
Alzheimer Disease Blood Biomarkers (4)
  1. Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline. Neurology · 16 Oct 2026 PMID 42886876
  2. The link between plasma and cognitive markers for Alzheimer's disease in Down syndrome: a longitudinal study. Journal of neurology · 24 Sept 2026 PMID 42786385
  3. Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome. Neurology · 1 Sept 2026 PMID 42679336
  4. Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases. Neurology · 13 Jul 2026 PMID 42441927
Neuroaxonal Injury Monitoring (3)
  1. Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study. Journal of neurology · 13 Sept 2026 PMID 42732528
  2. Plasma neurofilament light chain in type 2 diabetes: Associations with diabetic peripheral neuropathy, age, and renal function in a pilot cross-sectional study. PloS one · 9 Sept 2026 PMID 42715184
  3. Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort. Molecular neurobiology · 28 May 2026 PMID 42207242

By study type

Observational studies and case reports (15)
  1. Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline. Neurology · 16 Oct 2026 PMID 42886876
  2. Serum Complement Component 4A and Neurofilament Light Chain Levels Before and After Risperidone Monotherapy in Patients With Psychosis. Human psychopharmacology · 1 Oct 2026 PMID 42817153
  3. Evaluating the neurofilament light chain-derived gap between biological and chronological age in multiple sclerosis and controls. Journal of neurology · 27 Sept 2026 PMID 42802281
  4. The link between plasma and cognitive markers for Alzheimer's disease in Down syndrome: a longitudinal study. Journal of neurology · 24 Sept 2026 PMID 42786385
  5. Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study. Journal of neurology · 13 Sept 2026 PMID 42732528
  6. Plasma neurofilament light chain in type 2 diabetes: Associations with diabetic peripheral neuropathy, age, and renal function in a pilot cross-sectional study. PloS one · 9 Sept 2026 PMID 42715184
  7. The predictive value of serum neurofilament light chain levels beyond MRI measures for clinical and radiological disease progression in the earliest stages of multiple sclerosis. Journal of neurology · 9 Sept 2026 PMID 42714661
  8. Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP. Journal of neurology · 9 Sept 2026 PMID 42711449
  9. Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome. Neurology · 1 Sept 2026 PMID 42679336
  10. Real-world Roche Elecsys® and Fujirebio Lumipulse® inter-platform comparability and clinical validation of plasma neurofilament light chain in multiple sclerosis. Journal of neurology · 25 Aug 2026 PMID 42640285
  11. Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis. Neurology(R) neuroimmunology & neuroinflammation · 3 Aug 2026 PMID 42546229
  12. Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases. Neurology · 13 Jul 2026 PMID 42441927
  13. Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy. Liver international : official journal of the International Association for the Study of the Liver · 9 Jul 2026 PMID 42422896
  14. Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study. PloS one · 7 Jul 2026 PMID 42412876
  15. Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort. Molecular neurobiology · 28 May 2026 PMID 42207242
Human data, design not indexed (5)
  1. Exploring serum biomarkers in paediatric psychiatry: the impact of NfL and GFAP. Translational psychiatry · 26 Aug 2026 PMID 42649149
  2. Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses. Journal of neurology · 17 Jul 2026 PMID 42467089
  3. Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosis. Multiple sclerosis and related disorders · 30 Jun 2026 PMID 42378934
  4. Age-Dependent z Scores and eGFR-Adjusted Reference Ranges for Neurofilament Light: A Practical Approach for Clinical Laboratories. Clinical chemistry · 28 May 2026 PMID 42207013
  5. Differences in Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Tau Protein Levels in Patients with Temporal Lobe Epilepsy and Comorbid Depression. Molecular neurobiology · 26 May 2026 PMID 42189430